Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 2:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 382 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage IIIA Non Small Cell Lung Cancer Clear all
Terminated Phase 2 Interventional Results available

ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy

NCT04372927
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
Interventions
Cisplatin, Durvalumab, Etoposide, Hypofractionated Radiation Therapy, Pemetrexed
Drug · Biological · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Sep 20, 2026, 2:04 PM EDT
Terminated Not applicable Interventional

S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung Cancer

NCT00090961
View directory record Official record
Conditions
Lung Cancer, Pulmonary Complications
Interventions
educational intervention, supervised exercise program
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
60
States / cities
Fort Collins, Colorado • Decatur, Illinois • Maywood, Illinois + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Sep 20, 2026, 2:04 PM EDT
Terminated Phase 2 Interventional Results available

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

NCT04926831
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
capmatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
La Jolla, California • Sacramento, California • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 20, 2026, 2:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer

NCT00093756
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
3-dimensional conformal radiation therapy, bortezomib, paclitaxel, carboplatin
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
143
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 20, 2026, 2:04 PM EDT
Completed Phase 2 Interventional

Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery

NCT00057798
View directory record Official record
Conditions
Lung Cancer
Interventions
gemcitabine hydrochloride, vinorelbine ditartrate, cytogenetic analysis, loss of heterozygosity analysis, microarray analysis, conventional surgery, neoadjuvant therapy
Drug · Genetic · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Sep 20, 2026, 2:04 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

NCT02955290
View directory record Official record
Conditions
Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, PD-L1 Positive, Recurrent Head and Neck Squamous Cell Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma, Advanced Squamous Non-Small Cell Lung Carcinoma
Interventions
Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Other · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
5
States / cities
Indianapolis, Indiana • Buffalo, New York • Roslyn, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 20, 2026, 2:04 PM EDT
Recruiting Phase 1 Interventional

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

NCT03819296
View directory record Official record
Conditions
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Pathologic Stage 0 Cutaneous Melanoma AJCC v8, Pathologic Stage I Cutaneous Melanoma AJCC v8, Pathologic Stage IA Cutaneous Melanoma AJCC v8, Pathologic Stage IB Cutaneous Melanoma AJCC v8, Pathologic Stage II Cutaneous Melanoma AJCC v8, Pathologic Stage IIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIC Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Stage 0 Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Best Practice, Biospecimen Collection, Endoscopic Procedure, Fecal Microbiota Transplantation, Infliximab, Laboratory Biomarker Analysis, Prednisone, Vedolizumab
Other · Procedure · Biological + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 20, 2026, 2:04 PM EDT
Active, not recruiting Phase 3 Interventional Results available

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

NCT02511106
View directory record Official record
Conditions
Stage IB-IIIA Non-small Cell Lung Carcinoma
Interventions
AZD9291 80 mg/40 mg, Placebo AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
23
States / cities
Los Angeles, California • Santa Monica, California • Santa Rosa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 20, 2026, 2:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer

NCT00482014
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
pemetrexed, cisplatin, carboplatin, radiation therapy
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
9
States / cities
Los Angeles, California • Wichita, Kansas • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2012 · Synced Sep 20, 2026, 2:04 PM EDT
Active, not recruiting Not applicable Interventional

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

NCT02194738
View directory record Official record
Conditions
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Clinical Observation, Computed Tomography, Crizotinib, Cytology Specimen Collection Procedure, Echocardiography Test, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Placebo Administration, Positron Emission Tomography
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1655
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 20, 2026, 2:04 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

NCT03433469
View directory record Official record
Conditions
Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer, Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer
Interventions
Osimertinib, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Davis, California • San Francisco, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 20, 2026, 2:04 PM EDT
Not listed Phase 2 Interventional

Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

NCT00083083
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, docetaxel, etoposide, paclitaxel, vinblastine sulfate, vinorelbine tartrate, gene expression analysis, positron emission tomography, fludeoxyglucose F 18, radiation therapy
Drug · Genetic · Procedure + 1 more
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
46
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Sep 20, 2026, 2:04 PM EDT
Terminated Phase 2 Interventional Results available

Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT01935947
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Azacitidine, Docetaxel, Entinostat, Gemcitabine Hydrochloride, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pemetrexed Disodium
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Sep 20, 2026, 2:04 PM EDT
Terminated Phase 2 Interventional Results available

Induction Chemo-Nivo in Unresectable Stage III NSCLC

NCT06003075
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer Stage III
Interventions
Nivolumab and Chemotherapy, Nivolumab, Post Induction Surgery, Post Induction XRT
Combination Product · Drug · Procedure + 1 more
Lead sponsor
Ralph G Zinner
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 20, 2026, 2:04 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT00006378
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
3
States / cities
Morristown, New Jersey • New Brunswick, New Jersey • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Sep 20, 2026, 2:04 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma

NCT00003974
View directory record Official record
Conditions
Lung Cancer, Malignant Mesothelioma
Interventions
lung tumor associated antigen, DetoxPC, chemotherapy, cyclophosphamide
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
20 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2011 · Synced Sep 20, 2026, 2:04 PM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed

NCT00004160
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, gemcitabine hydrochloride, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Sep 20, 2026, 2:04 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer

NCT00924209
View directory record Official record
Conditions
NSCLC, Stage IIIA (N2)
Interventions
Gemcitabine, Cisplatin, Bevacizumab, Surgery, Etoposide
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Sep 20, 2026, 2:04 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

NCT00020709
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
cisplatin, docetaxel, etoposide, gefitinib, radiation therapy, placebo
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Sep 20, 2026, 2:04 PM EDT
Completed Phase 1 Interventional

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

NCT00004065
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
tanespimycin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 20, 2026, 2:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients

NCT01999881
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Healthy, no Evidence of Disease, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
exercise intervention, standard follow-up care, quality-of-life assessment, laboratory biomarker analysis
Behavioral · Procedure · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 20, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

NCT01935336
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
Ponatinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Sep 20, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer

NCT01507428
View directory record Official record
Conditions
Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions
18F-Fluoromisonidazole, Carboplatin, Computed Tomography, External Beam Radiation Therapy, Fludeoxyglucose F-18, Image-Guided Adaptive Radiation Therapy, Laboratory Biomarker Analysis, Paclitaxel, Positron Emission Tomography
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
29
States / cities
Palo Alto, California • Augusta, Georgia • Chicago, Illinois + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 20, 2026, 2:04 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

NCT03225664
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Pembrolizumab, Pharmacokinetic Study, Trametinib
Biological · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 20, 2026, 2:04 PM EDT